HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells.

AbstractBACKGROUND:
Attachment of leukemic cells to vascular endothelial cells induces the vascular endothelial cells to release endothelial cell-derived interleukin 8 (endothelial IL-8), which then induces leukemic cells to undergo apoptosis. NB4, a human promyelocytic leukemic cell line that expresses high levels of cell-surface CD13/aminopeptidase N, does not undergo endothelial IL-8-induced apoptosis. Consequently, we investigated the relationship between cell-surface aminopeptidase activity and endothelial IL-8 induction of apoptosis in various leukemic cell lines.
METHODS:
CD13/aminopeptidase N activity and IL-8-induced apoptosis were examined in leukemic cell lines. Endothelial IL-8-induced apoptosis was examined further in NB4 cells, K562 cells (human chronic myelogenous leukemic cells expressing low levels of CD13/aminopeptidase N), CD13/aminopeptidase N-transfected K562 (K562/CD13) cells that overexpress aminopeptidase, and mock-transfected K562 cells (vector only). These cells were also cocultured with a vascular endothelial cell layer to investigate the association between aminopeptidase activity and apoptosis in this system. All statistical tests were two-sided.
RESULTS:
Endothelial IL-8 induced apoptosis in K562 cells but not in K562/CD13 cells. A combination of an aminopeptidase inhibitor (such as bestatin) and endothelial IL-8 induced apoptosis in NB4 cells and K562/CD13 cells (2.88-fold difference [95% confidence interval [CI] = 1.82-fold to 3.94-fold], P =.004 for bestatin-treated NB4 cells and 4.31-fold difference [95% CI = 3.52-fold to 5.10-fold], P<.001 for bestatin-treated K562/CD13 cells). When aminopeptidase activity in NB4 cells was modulated by aminopeptidase inhibitors, a statistically significant correlation was found between aminopeptidase activity and the proportion of apoptotic cells induced by endothelial IL-8 (r = -.837, P<.001 by Pearson's correlation coefficient; r = -.697, P =.013 by Spearman's correlation analysis by ranks). K562/CD13 cells cocultured with vascular endothelial cells did not undergo apoptosis, but the addition of bestatin resulted in the induction of apoptosis in K562/CD13 cells (2.70-fold difference [95% CI = 1.77-fold to 3.63-fold], P<.001). Bestatin treatment increased the level of IL-8 mRNA in and the amount of IL-8 secreted by vascular endothelial cells.
CONCLUSIONS:
High levels of cell-surface CD13/aminopeptidase N appear to allow leukemic cells to resist endothelial IL-8-induced apoptosis. The combination of endothelial IL-8 and bestatin induce leukemic cells expressing high levels of CD13/aminopeptidase N to undergo apoptosis. Bestatin may be useful for treating patients with leukemia.
AuthorsYuji Mishima, Yuko Matsumoto-Mishima, Yasuhito Terui, Misa Katsuyama, Muneo Yamada, Masaki Mori, Yukihito Ishizaka, Kazuma Ikeda, Jun-ichiro Watanabe, Nobuyuki Mizunuma, Hirotoshi Hayasawa, Kiyohiko Hatake
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 94 Issue 13 Pg. 1020-8 (Jul 03 2002) ISSN: 0027-8874 [Print] United States
PMID12096087 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibiotics, Antineoplastic
  • Interleukin-8
  • CD13 Antigens
  • Leucine
  • ubenimex
Topics
  • Antibiotics, Antineoplastic (pharmacology)
  • Apoptosis (drug effects, physiology)
  • Blotting, Northern
  • CD13 Antigens (antagonists & inhibitors, genetics, metabolism)
  • Cell Division (drug effects)
  • Cells, Cultured
  • Endothelium, Vascular (physiology)
  • Fluorescent Antibody Technique
  • Humans
  • In Situ Nick-End Labeling
  • Interleukin-8 (metabolism, pharmacology, physiology)
  • K562 Cells (pathology)
  • Leucine (analogs & derivatives, pharmacology)
  • Leukemia (pathology)
  • Transfection
  • Umbilical Veins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: